Eton Pharmaceuticals Performance degli utili passati
Criteri Il passato verificati 3/6
Eton Pharmaceuticals ha registrato una crescita degli utili a un tasso medio annuo di 35.9%, mentre il settore Pharmaceuticals ha registrato utili in crescita a un tasso medio annuo di 13.5%. I ricavi sono stati in crescita a un tasso medio annuo di 38.6%. Il ritorno sul capitale proprio di Eton Pharmaceuticals è 27.2% e ha margini netti di 12%.
Informazioni chiave
35.88%
Tasso di crescita degli utili
37.01%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 5.95% |
| Tasso di crescita dei ricavi | 38.55% |
| Rendimento del capitale proprio | 27.24% |
| Margine netto | 12.02% |
| Ultimo aggiornamento sugli utili | 30 Jun 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento narrativa • Sep 09
ETON: Hemangioma Portfolio Momentum Will Drive Future Ultra Rare Upside
Analysts have lifted their fair value estimate for Eton Pharmaceuticals to $68 from $60, citing stronger contributions from Hemangeol, upgraded revenue and margin guidance, and added long-term pipeline expectations reflected in a higher future P/E assumption. Analyst Commentary Recent Street research on Eton Pharmaceuticals has focused on strong reported Q2 results, higher revenue and margin guidance, and increasing confidence in the commercial outlook for Hemangeol and other portfolio assets.
Aggiornamento narrativa • Aug 26
ETON: Pediatric Rare Disease Focus Will Drive Upside From Hemangioma Franchise Expansion
Analysts have raised their fair value estimate for Eton Pharmaceuticals from $62.00 to $76.00, citing higher modeled revenue growth and a higher future P/E multiple supported by recent price target increases following strong Q2 results and Hemangeol performance. Analyst Commentary Recent Street commentary on Eton Pharmaceuticals has been broadly constructive, with multiple bullish analysts lifting their price targets following Q2 results.Articolo di analisi • Aug 19
Forecast: Analysts Think Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Business Prospects Have Improved Drastically
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Aug 14
Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These
Summary Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales by leveraging organic growth, pipeline development, and strategic acquisitions in rare disease markets. Management expects adjusted EBITDA margins to exceed 35% in 2026, aiming for 50% by 2028, with gross margins rising from 70% to over 75%. I rate ETON stock a Buy, supported by robust execution, scalable commercial strategy, and a 2-3 year target valuation above $2.5 billion despite current premium multiples. Read the full article on Seeking AlphaAggiornamento narrativa • Aug 12
ETON: Ultra Rare Focus And New Guidance Will Drive Future Upside
Analysts have raised the fair value estimate for Eton Pharmaceuticals from $40 to $60. This change reflects updated models that factor in higher long term revenue assumptions for key products and recent price target increases across several research firms.Aggiornamento narrativa • Jul 28
ETON: Ultra Rare Disease Focus Will Drive Long Term Upside Potential
Analysts lifted the fair value estimate for Eton Pharmaceuticals to $62 from $57, reflecting updated price targets in the $60 to $62 range that factor in new product contributions, higher long term revenue assumptions for existing therapies, and more constructive views on its ultra rare disease portfolio. Analyst Commentary Recent Street research on Eton Pharmaceuticals points to a more constructive tone around the stock, with bullish analysts lifting price targets into the US$60 to US$62 range.Aggiornamento narrativa • Jul 13
ETON: New Guidance And Drug Agreement Will Shape A Balanced Outlook
The analyst price target for Eton Pharmaceuticals has been raised from $52 to $57, with analysts citing updated fiscal 2026 revenue guidance and confidence in the company's growth strategy as key reasons for the change. What’s in the News for Eton Pharmaceuticals Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals, sold about 126,685 shares for roughly US$4.77 million between July 2 and July 7, 2026, at weighted average prices near US$37 to US$38 per share, while retaining around 2.7 million shares (source: recent SEC filings summarized in news reports).
Aggiornamento narrativa • Jun 29
ETON: Orphan Therapy Portfolio Expansion Will Reshape Earnings Profile Through 2026
Eton Pharmaceuticals' analyst price targets have moved higher, with fair value estimates rising from about $39.33 to $45.67, as analysts point to updated revenue guidance and increased confidence in the company’s longer term growth plans. What’s in the News for Eton Pharmaceuticals Eton Pharmaceuticals was added to the S&P Pharmaceuticals Select Industry Index, reflecting its inclusion in a broader sector benchmark.Aggiornamento narrativa • Jun 15
ETON: Higher 2026 Revenue Outlook Will Support Long Term Upside Potential
Analysts have raised their price target on Eton Pharmaceuticals to $57 from $52, citing the company's updated fiscal 2026 revenue guidance and their view that its long term growth goals remain achievable. Analyst Commentary Bullish analysts are pointing to Eton Pharmaceuticals' updated fiscal 2026 revenue guidance as a key support for their higher valuation frameworks.Aggiornamento narrativa • Jun 01
ETON: Higher 2026 Guidance And New Rare Disease Assets Will Drive Upside
Analysts have lifted their fair value estimate for Eton Pharmaceuticals to $57 from $35, citing higher fiscal 2026 revenue guidance, stronger profitability assumptions, and confidence in the company’s growth strategy as key reasons for the revised valuation. Analyst Commentary Recent research updates show a clear cluster of bullish analysts raising their fair value assumptions on Eton Pharmaceuticals, with several target bumps tied directly to the company’s latest revenue outlook and portfolio moves.Aggiornamento narrativa • May 03
ETON: Single New Acquisition Will Reshape Earnings Profile Through 2026 And Beyond
Analysts have lifted their price targets on Eton Pharmaceuticals by up to $15, citing updated assumptions for revenue growth, profit margins, and future P/E that reflect the recent Hemangeol acquisition and its potential contribution to the business. Analyst Commentary Recent research updates around Eton Pharmaceuticals focus heavily on the Hemangeol acquisition and how it might reshape the company’s growth mix, earnings profile, and valuation assumptions.Aggiornamento narrativa • Apr 18
ETON: Hemangioma Acquisition Will Reshape Earnings Profile Through 2026 And Beyond
Narrative Update on Eton Pharmaceuticals Analysts have raised their price targets on Eton Pharmaceuticals by up to $15, citing the Hemangeol acquisition, its existing FDA approval for infantile hemangioma, and the view that the deal could be accretive with commercialization planned to begin in May. Analyst Commentary Bullish analysts are generally positive on Eton Pharmaceuticals following the acquisition of the U.S. rights to Hemangeol, and several have raised their price targets in response.Aggiornamento narrativa • Apr 04
ETON: Hemangioma Franchise Expansion Will Reshape Earnings Profile Through 2026
Analysts have raised the consolidated price target for Eton Pharmaceuticals from $30.00 to about $39.33, citing recent target increases from multiple firms and updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research around Eton Pharmaceuticals focuses heavily on the updated price targets, the Hemangeol acquisition, and how realistic current modeling assumptions appear against execution risks.Aggiornamento narrativa • Mar 21
ETON: Upcoming Product Launches And New Guidance Will Reshape Earnings Profile
Analysts have raised the Eton Pharmaceuticals price target from $26 to $31, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that reflect their latest views on the company following recent research updates. Analyst Commentary Recent research updates highlight a mix of optimism about Eton Pharmaceuticals' growth opportunities and caution around how quickly those opportunities might translate into earnings and justify higher valuation multiples.Articolo di analisi • Nov 14
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Share Price Matching Investor Opinion
With a price-to-sales (or "P/S") ratio of 6.4x Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) may be sending very bearish...Articolo di analisi • Sep 24
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Jun 17
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 25% Cheaper Price Remains In Tune With Revenues
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a horrible month, losing 25% after a relatively good period...Nuova narrativa • May 16
Increlex And Galzin Acquisitions Will Broaden Treatment Options
Strategic acquisitions and product launches are expected to drive significant revenue growth and expand market reach in pediatrics and rare diseases.Articolo di analisi • May 16
Results: Eton Pharmaceuticals, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
It's been a pretty great week for Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders, with its shares surging 14...Articolo di analisi • May 02
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 33%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders are no doubt pleased to see that the share price has bounced...Articolo di analisi • Feb 07
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 45% Jump Shows Its Popularity With Investors
Despite an already strong run, Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have been powering on, with a gain of...Articolo di analisi • Nov 14
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%
Despite an already strong run, Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have been powering on, with a gain of...Articolo di analisi • Oct 07
Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Sep 10
After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar
The Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) share price has done very well over the last month, posting an excellent...Articolo di analisi • Jan 09
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a really impressive month, gaining 40% after a shaky period...Articolo di analisi • Dec 13
The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Market forces rained on the parade of Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders today, when the covering...Articolo di analisi • Nov 16
Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Eton Pharmaceuticals, Inc.'s ( NASDAQ:ETON ) earnings announcement last week was disappointing for investors, despite...Articolo di analisi • Sep 30
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Jul 25
Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a horrible month, losing 26% after a relatively good period...Articolo di analisi • Jun 29
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Eton Pharmaceuticals guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 26 | 106 | 13 | 38 | 6 |
| 31 Mar 26 | 87 | -1 | 37 | 8 |
| 31 Dec 25 | 80 | -5 | 35 | 8 |
| 30 Sep 25 | 70 | -7 | 33 | 5 |
| 30 Jun 25 | 58 | -4 | 30 | 5 |
| 31 Mar 25 | 48 | -5 | 26 | 4 |
| 31 Dec 24 | 39 | -4 | 22 | 3 |
| 30 Sep 24 | 35 | -5 | 21 | 5 |
| 30 Jun 24 | 31 | -7 | 20 | 5 |
| 31 Mar 24 | 34 | 1 | 19 | 3 |
| 31 Dec 23 | 32 | -1 | 19 | 3 |
| 30 Sep 23 | 33 | 2 | 19 | 3 |
| 30 Jun 23 | 29 | 0 | 19 | 3 |
| 31 Mar 23 | 24 | -6 | 19 | 3 |
| 31 Dec 22 | 21 | -9 | 19 | 4 |
| 30 Sep 22 | 19 | -9 | 18 | 4 |
| 30 Jun 22 | 16 | -12 | 17 | 6 |
| 31 Mar 22 | 12 | -12 | 15 | 7 |
| 31 Dec 21 | 22 | -2 | 14 | 6 |
| 30 Sep 21 | 16 | -11 | 14 | 9 |
| 30 Jun 21 | 15 | -11 | 15 | 9 |
| 31 Mar 21 | 12 | -14 | 14 | 9 |
| 31 Dec 20 | 0 | -28 | 13 | 14 |
| 30 Sep 20 | 0 | -23 | 11 | 11 |
| 30 Jun 20 | 1 | -21 | 10 | 11 |
| 31 Mar 20 | 1 | -20 | 9 | 11 |
| 31 Dec 19 | 1 | -18 | 8 | 12 |
| 30 Sep 19 | 1 | -42 | 6 | 12 |
| 30 Jun 19 | 1 | -40 | 6 | 11 |
| 31 Mar 19 | 1 | -41 | 5 | 11 |
| 31 Dec 18 | 0 | -37 | 5 | 6 |
| 30 Sep 18 | 0 | -18 | 6 | 7 |
Guadagni di qualità: ETON ha un livello elevato di guadagni non monetari.
Margine di profitto in crescita: ETON è diventata redditizia in passato.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: ETON è diventata redditizia negli ultimi 5 anni, aumentando i guadagni del 35.9% all'anno.
Accelerare la crescita: ETON è diventata redditizia nell'ultimo anno, rendendo difficile confrontare il tasso di crescita degli utili con la media quinquennale.
Guadagni vs Settore: ETON è diventata redditizia nell'ultimo anno, rendendo difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Pharmaceuticals ( 1% ).
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 27.2% ) di ETON è considerato alto.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/21 19:46 |
| Prezzo dell'azione a fine giornata | 2026/09/21 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Eton Pharmaceuticals, Inc. è coperta da 6 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Gary Nachman | Canaccord Genuity |